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ADH = atypical ductal hyperplasia; ALH = atypical lobular hyperplasia; CGH = comparative genomic hybridisation; DCIS = ductal carcinoma in
situ; HUT = hyperplasia of usual type; LCIS = lobular carcinoma in situ; LOH = loss of heterozygosity; NST = no special type.
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Introduction
The multistep model of breast carcinogenesis suggests a
transition from normal epithelium to invasive carcinoma via
non-atypical and atypical hyperplasia and in situ carci-
noma. Within the breast, these proliferations are heteroge-
neous in their cytological and architectural characteristics.
The introduction of mammographic screening has led to
the increased detection of pre-invasive disease and has
highlighted deficiencies in our understanding and classifi-
cation of such lesions. The morphological classification of
pre-invasive lesions of the breast remains controversial
and there has been hope that molecular analysis will clarify
the uncertainties.
A multitude of methods have been used for the characteri-
sation of pre-invasive breast lesions, including immunohis-
tochemistry, fluorescent in situ hybridisation, analysis of
loss of heterozygosity (LOH), comparative genomic
hybridisation (CGH), and, more recently, cDNA micro-
arrays and proteomics analysis. In this review, we have
mainly focused on the genetic abnormalities in pre-inva-
sive lesions of the breast as detected by LOH and CGH
analysis (Table 1). The other techniques have been
addressed elsewhere in the series.
Ductal carcinoma in situ
The analysis of genetic alterations in ductal carcinoma in
situ (DCIS) has provided new insights in the biology of
these lesions. As with invasive carcinoma, abnormalities of
chromosomes 1 and 16 have been identified in some of
these cases [1]. The CGH method has been modified for
paraffin-embedded material and this has allowed studies
on archival material and, in particular, the study of pre-inva-
sive disease [2–8]. CGH analysis of DCIS has demon-
strated a large number of alterations, including gains of
1q, 5p, 6q, 8q, 17q, 19q, 20p, 20q, and Xq, and losses of
2q, 5q, 6q, 8p, 9p, 11q, 13q, 14q, 16q, 17p, and 22q
[2–8]. These alterations are similar to those identified in
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Abstract
The development of modern molecular genetic techniques has allowed breast cancer researchers to
clarify the multistep model of breast carcinogenesis. Laser capture microdissection coupled with
comparative genomic hybridisation and/or loss-of-heterozygosity methods have confirmed that many
pre-invasive lesions of the breast harbour chromosomal abnormalities at loci known to be altered in
invasive breast carcinomas. Current data do not provide strong evidence for ductal hyperplasia of
usual type as a precursor lesion, although some are monoclonal proliferations; however, atypical
hyperplasia and in situ carcinoma appear to be nonobligate precursors. We review current knowledge
and the contribution of molecular genetics in the understanding of breast cancer precursors and pre-
invasive lesions.
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invasive carcinoma, adding weight to the idea that DCIS is
a precursor lesion.
Several lines of evidence support the concept that differ-
ent types of DCIS show different genetic alterations, sug-
gesting that there may be multiple pathways for the
evolution of DCIS [4,6,8,9]. Alterations at 16q are much
more frequent in low-grade DCIS than in high-grade
DCIS, in which alterations at 13q, 17q, and 20q are more
frequent [4,6,7,10]. Similar findings in invasive carcinomas
of low and high grade also support the idea that low-grade
and high-grade lesions develop through distinct pathways
rather than by dedifferentiation [4,6,7,10]. With the use of
microdissection techniques to isolate small microscopic
lesions, loss of heterozygosity (LOH) has also been inves-
tigated in pre-invasive disease [11–17]. O’Connell and
colleagues [11] studied pre-invasive lesions using a
variety of chromosomal markers and showed that 50% of
the proliferative lesions and 80% of the DCIS shared their
LOH patterns with invasive carcinoma. Stratton and col-
leagues [12] studied cases of DCIS associated with inva-
sive carcinoma and cases of ‘pure’ DCIS without an
invasive component using a limited set of microsatellite
markers on chromosomes 7q, 16q, 17p, and 17q. They
found a similar frequency of LOH in both subsets of DCIS
to invasive carcinoma, providing further strong evidence
Table 1
Summary of the genetic abnormalities detected in pre-invasive lesions of the breasta
Lesion Method Gainsb Losses / LOH / AIb Reference
Normal cells LOH – 2pter, 16q23.1–24.2, 17q21, 17q24 [17]
LOH – 9p, 11p, 13q, 16q, 17p [56]
LOH – 3p24, 11p15.5, 17p13.1 [60]
LOH – 1q, 7q, 11p, 16q, 17q [61]
LOH – 11p, 13q [63]
LOH – 3p24.3 [64]
HUT CGH No No [6]
LOH – 2pter, 2q35, 4q25, 6qter, 8p, 9p, 11p15, 11q23, 13q13, 14q24, 16q21, 17p13, 17q11, [13]
17q21, 17q25
CGH 1q+, 1q32–42+, 8-, 8p12-pter-, 9-, 10p-, 11q14-qter-, 18-, X-, 16q-, 17p-, 20p- [54]
12+, 17q21+, 20+
LOH – 16q, 17p, 17q [55]
LOH – 9p, 11p, 13q, 16q, 17q [56]
CGH 13q 1p, 16p, 17q, 19p, 22q [57]
ADH LOH – 2pter, 2q35, 6qter, 8p, 9p, 11p15, 11q23, 13q13, 14q24, 16q21, 17p13, 17q11, 17q21, [13]
LOH – 17q25, 16q, 17p [52]
LOH – 8p, 16q, 17q [53]
CGH 1q, 10, 16p, 3q11-q21, 8p12-pter, 16q,20, 11q12-13, 16q 16q, 20p, 16q, 17p, 21q11-q21, 16q, 17p [54]
8q21-qter, 14q
ALH/LCIS CGH 1q, 1q21-q32, 7p, 8p, 8p21-pter, 12q24, 16q, 17p, 13q12-q21; 16q; 17p12-p13 [31]
1q25-qter, 8p11-p12,
12q14-q21
CGH 6q 16p, 16q, 17p, 22q [32]
Columnar LOH – 2p, 3p, 11q, 11q, 16q, 16q, 17q, 17q [60]
cell change
/clinging ca
DCISc See text See text See text See text
–, none. aFor LOH analyses, only those studies in which more than one chromosomal arm was evaluated were included in the table. bAll
chromosomal gains and losses reported in the cited studies (references) were included. For the frequency of each genetic abnormality, please see
text and cited references. cDCIS of different grades harbour distinct chromosomal abnormalities. Genetic abnormalities of nearly all chromosomal
arms have been reported in high-grade DCIS. See text for details. ADH, atypical ductal hyperplasia; AI, allelic imbalance; ALH/LCIS, atypical
lobular hyperplasia/lobular carcinoma in situ; Columnar cell change/ clinging ca, columnar cell change/clinging carcinoma; DCIS, ductal carcinoma
in situ; HUT, hyperplasia of usual type; LOH, loss of heterozygosity.
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that DCIS is likely to be a precursor of invasive carcinoma.
Several other reports corroborating these seminal studies
have been published [13–20].
c-erbB2 (Her-2/neu) protein has been identified in a high
proportion (60–80%) of DCIS of high-nuclear-grade
comedo type but is not common in the low-nuclear-grade
forms. Allred and colleagues [21] showed that the expres-
sion is higher in invasive carcinoma associated with DCIS
than in those without DCIS. This oncogene is very rarely
overexpressed in classic lobular carcinoma in situ (LCIS)
and its overexpression has been occasionally observed in
cases of pleomorphic lobular carcinoma in situ [22,23].
There is no evidence that c-erbB2 is amplified or overex-
pressed at the protein level in benign proliferative breast
diseases or atypical ductal hyperplasia (ADH) [24], which
may suggest that c-erbB2 is important in the transition
from a ‘benign’ to a ‘malignant’ phenotype. The difference
in frequencies of expression in in situ and invasive carci-
noma remains a mystery. A number of hypotheses have
been advanced, suggesting either that the expression is
switched off during invasion or that many c-erbB2-positive
DCIS do not transform to invasive malignancy. Expression
of p53 protein has been demonstrated using immunohis-
tochemistry in high-nuclear-grade DCIS (comedo type)
[25]. The mechanism may be gene mutation, but this has
been confirmed in only some cases. Like c-erbB2, p53
protein expression is rare in LCIS and has not been
demonstrated in atypical ductal hyperplasia or other
benign proliferative disease [26]. Done and colleagues
[27] demonstrated that p53 mutations found in DCIS and
associated invasive cancer were absent from benign pro-
liferative lesions from the same breast.
In summary, a considerable body of evidence indicates
that DCIS, particularly of high grade, shares many molecu-
lar genetic alterations with invasive carcinoma
[4–8,14,15]. Therefore, high-grade DCIS should be con-
sidered a direct precursor of invasive carcinoma. More-
over, gain of chromosome 1q and loss of 16q, which are
highly prevalent in low-grade DCIS, are frequently found in
tubular carcinoma and in tubular, tubulolobular, lobular,
and grade 1 invasive ductal carcinomas [4,6,8,28], sug-
gesting that low-grade DCIS is also a direct precursor for
certain types of breast carcinomas.
Lobular carcinoma in situ
Lobular carcinoma in situ of the breast is an uncommon
lesion with a distinctive appearance. It is classically com-
posed of discohesive cells with small, monomorphic,
hyperchromatic nuclei; however, a pleomorphic variant has
been described [23,29]. It is occasionally confused with
DCIS of low-grade, solid type; however, epidemiological
studies show that its biological behaviour and clinical
implications are quite different from those of DCIS. It is
usually an incidental finding and is not visible on mammo-
graphy [29]. The lesions are multifocal and bilateral in a
high proportion of cases [29]. The majority of cases are
diagnosed in patients aged between 40 and 50 years, a
decade earlier than DCIS. Approximately one-fifth of the
cases will progress to invasive cancer over a 20- to
25-year follow-up period [29]. Although invasive ductal
carcinomas, especially of tubular type, do occur after
LCIS, most cases associated with LCIS are infiltrating
lobular carcinoma [29]. It has been said that the risk is
equal for the two breasts [30]; however, there are data to
suggest that the risk is skewed in favour of the ipsilateral
breast [29,31]. Despite these thorny issues, the epidemio-
logical and pathological features of LCIS have raised
questions about its biological nature, and some still con-
sider it a ‘marker of increased risk’ rather than a true pre-
cursor of invasive carcinoma.
In our laboratories, we have carried out CGH analysis on
LCIS and atypical lobular hyperplasia [32]. Loss of mater-
ial from 16p, 16q, 17p, and 22q and gain of material from
6q have been found at similar high frequencies in both
LCIS and atypical lobular hyperplasia. Losses at 1q, 16q,
and 17p have also been seen in invasive lobular carcino-
mas [8,33]. LOH data in LCIS are also limited but do
demonstrate a similarity between LCIS and infiltrating
lobular carcinoma [34,35].
E-cadherin is a candidate tumour suppressor protein
coded by a gene on 16q22.1, which is involved in
cell–cell adhesion and in cell-cycle regulation through the
β-catenin/Wnt pathway [36]. The majority of invasive
ductal carcinomas of no special type (NST) usually exhibit
positive staining by immunohistochemistry, whereas the
overwhelming majority of invasive lobular carcinomas are
negative [37–39]. E-cadherin truncating mutations associ-
ated with loss of the wild-type allele (LOH at 16q) have
been observed in LCIS and invasive lobular carcinomas
[38,40,41]. Berx and colleagues [40] failed to identify any
truncating mutations in invasive ductal carcinomas of NST
or medullary carcinomas; similar findings were recently
reported by Roylance and colleagues [39], who demon-
strated lack of E-cadherin mutations in 44 low-grade
ductal carcinomas of NST. E-cadherin is expressed in
normal epithelium and in most of the cases of DCIS, but
staining is rarely seen in LCIS [23,38,39,42–46]. Based
on this differential expression of E-cadherin in LCIS and
DCIS, some authors have advocated the use of antibodies
against E-cadherin as an adjunct marker for the differentia-
tion of LCIS from DCIS [23,44–47].
In addition, Vos and colleagues [41] have demonstrated
the same truncating mutation in the E-cadherin gene in
LCIS and the adjacent invasive lobular carcinoma. The
data provide strong evidence for the role of the E-cadherin
gene in the pathogenesis of lobular lesions and also
support the hypothesis of a precursor role for LCIS.
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Although E-cadherin germline mutations have been impli-
cated in the pathogenesis of familial diffuse gastric carci-
noma, there are only anecdotal case reports of lobular
carcinoma arising in patients with germline alteration in the
gene [36]. In contrast, Rahman and colleagues [46] failed
to find any pathogenic E-cadherin germline mutations in
65 patients with LCIS and positive family history of breast
carcinoma, thus suggesting that E-cadherin is unlikely to
act as a susceptibility gene for LCIS.
Atypical ductal hyperplasia
ADH is a controversial lesion, which shares some but not
all features of DCIS. It poses considerable difficulties in
surgical histopathology. In order to address this problem,
Page and Rogers [48] laid down criteria for the diagnosis
of this entity. Rosai [49] in his study had demonstrated a
high interobserver variability in the diagnosis of ADH.
However, a subsequent study by Schnitt and colleagues
[50], in which the pathologist used Page’s criteria,
showed an improvement, with complete agreement in
58% of cases. Within the UK National External Quality
Assessment Scheme [51], agreement even among experi-
enced breast pathologists has been low. Lakhani and col-
leagues [52] demonstrated that LOH identified at loci on
16q and 17p in invasive carcinoma and DCIS is also
present in ADH with a similar frequency. Similar results
were reported by Amari and colleagues [53]. O’Connell
and colleagues [13] studied 51 cases of ADH at 15 poly-
morphic loci and found LOH at at least one marker in 42%
of the cases. The studies demonstrate that morphological
overlaps are reflected at the molecular level and raise
questions about the validity of separating ADH from DCIS.
CGH analysis of nine cases of ADH revealed chromoso-
mal abnormalities in five of them [54]. As expected, owing
to the morphological overlap with low-grade DCIS, losses
of 16q and 17p were the most frequent changes found in
ADH [54].
Hyperplasia of usual type
O’Connell and colleagues [13] demonstrated that LOH at
many different loci can be identified in hyperplasia of usual
type (HUT), with frequencies ranging from 0 to 15%.
These figures are similar to those of Lakhani and col-
leagues [55], who reported data in non-atypical hyperpla-
sia (HUT) dissected from benign breast biopsies. LOH
was identified at frequencies ranging from 0 to 13% at a
locus on 17q. These frequencies are much lower than
those identified in DCIS and ADH (range 25–55%). In the
series reported by Washington and colleagues [56], 4 of
21 HUTs showed LOH in one to five loci. LOH at 16q
(three cases), 9p (three cases), and 13q (two cases) were
the most frequent findings [56]. Although CGH analysis of
HUTs has demonstrated that the majority of these lesions
harbour no chromosomal abnormalities [6,55–57], the
picture dramatically changes when they are associated
with ADH or DCIS [54]. In this setting, most lesions show
losses of 16q and 17p [54]. In our view, the majority of
HUTs do not appear to be precursors of DCIS and IDC,
but the precursor potential of a small subset of these
lesions cannot be excluded based on the reports of syn-
chronous HUT and invasive breast cancer sharing a
common genetic lineage [13].
A word of caution should be voiced, as in the majority of
the studies published to date, the contamination of HUTs
with neoplastic cells of ADH and DCIS could not be
excluded. This issue was recently addressed in a study
published by Jones and colleagues [57], in which the
authors analysed 14 cases of bilateral HUTs (28 lesions)
by CGH. To avoid the inclusion of dubious lesions or cont-
amination of HUTs with neoplastic cells, the authors
defined HUTs according to the criteria proposed by the
Pathology Working Group on Behalf of the Breast
Screening Program and immunohistochemically with anti-
bodies against cytokeratins 5/6. In that study [57], 18 of
28 lesions from 10 of 14 patients harboured chromosomal
abnormalities, which ranged from 0 to 5, with a mean of
1.6. The most common genetic alterations were gains of
13q and losses at 1p, 16p, 17q, 19p, and 22q. When
paired HUTs from the same patients were compared, only
five concordant genetic abnormalities were observed, and
only one of these appeared more than once (loss of 17q,
in two cases). These findings corroborated those
reported by O’Connell and colleagues [13], who evalu-
ated multiple foci of HUT affecting the same breast
(53 breasts) and found that only 15% of the lesions
within the same breast shared their LOH phenotype. Alto-
gether, owing to limitations imposed by the currently
available methodology, it seems that a relatively small pro-
portion of HUTs are monoclonal, neoplastic proliferations,
but the evidence in support of HUT as a precursor of
DCIS and IDC is still weak.
Columnar cell lesions
Columnar cell lesions have been a major source of confu-
sion among breast pathologists, first because they have
been reported under several different names, including
columnar alteration of lobules, blunt duct adenosis, meta-
plasie cylindrique, cancerisation of small ectatic ducts of
the breast by ductal carcinoma in situ cells with apocrine
snouts [58], columnar alteration with prominent apical
snouts and secretions [59], and clinging carcinoma in situ
[60]. These lesions represent a spectrum that ranges from
columnar cell alteration in luminal cells to ADH and
flat/clinging DCIS. Regardless of the fact that there are
several lines of evidence showing an association with
tubular carcinoma [59,60], only one paper has addressed
the genetic abnormalities in these lesions [60]. Moinfar
and colleagues [60] demonstrated that 77% of columnar
cell lesions (either with or without atypia) harbour chromo-
somal abnormalities at least in one locus and the most fre-
quent loci of LOH were 11q21–23.2, 16q23.1–24.2, and
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3p14.2 [60]. It is noteworthy that 16q and 11q are fre-
quently lost in tubular carcinomas [28,60]. More interest-
ingly, these authors [60] have also shown that otherwise
luminal cells with mild nuclear atypia lining ducts at the
vicinity of columnar cell lesions may also have loss of
genetic material in up to 6% of the cases.
Normal tissues
Over the past few years, seven studies have also demon-
strated that LOH identified in invasive carcinoma is
already present in morphologically normal lobules
[17,36,56,61–64]. Lakhani and colleagues [63] demon-
strated that LOH identified in normal breast epithelial cells
is seen independently in luminal and myoepithelial cells,
suggesting a common precursor cell for these two types
of epithelial cell. Even more thought provoking is the data
published by Moinfar and colleagues [17], who demon-
strated the presence of concurrent and independent
genetic alterations in normal-appearing stromal and
epithelial cells located either in the vicinity of or at a dis-
tance from the foci of DCIS or IDC. The extent and fre-
quency of alterations and their significance in the
multistep carcinogenesis remain unknown at present. It
should be noted that in breasts without malignant
changes, genetic alterations in normal cells are rather
infrequent, subtle, and fairly random [6]. Conversely, one
paper has demonstrated that normal lobules and adjacent
in situ carcinomas show concordant genetic alterations
[17], and another suggested that LOH in lobular units in
terminal ducts in the normal breast is predictive of local
recurrence [64].
Conclusion
Molecular biology and genetics have provided new
insights for the comprehension of biology of pre-invasive
lesions of the breast. CGH and LOH studies have partially
corroborated the multistep model of breast carcinogene-
sis by demonstrating similar chromosomal abnormalities in
ADH and DCIS. More interestingly, these findings chal-
lenge the concept of HUT as a precursor of breast cancer
and suggest that columnar cell alteration may be a pecu-
liar form of pre-invasive lesion and, possibly, a precursor of
low-grade invasive ductal carcinomas of the breast. These
techniques have also demonstrated that different types of
in situ breast carcinoma harbour different chromosomal
abnormalities, and these findings may reflect the involve-
ment of different pathways in the multistep model of
breast carcinogenesis.
We are still in the early phase of molecular analysis of pre-
invasive lesions. Dramatic advances in the understanding
of these lesions may be expected with the development of
more flexible microdissection systems (suitable for
fresh/frozen samples) and the advent of high-throughput-
technology methods suitable for the evaluation of paraffin-
embedded tissues (e.g. CGH arrays).
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